Dynavax Technologies Corp. (NASDAQ:DVAX) currently has a daily average trading volume of 2.02M but it saw 1869530 shares traded in last market. With a market cap of 1.58B USD, the company’s current market price of $12.10 came rising about 0.67 while comparing to the previous closing price of $12.02. In past 52 weeks, the stock remained buoying in the range of price level as high as $15.15 and as low as $9.48.
Taking a look at 20-day trading activity of Dynavax Technologies Corp. (DVAX) gives us an average price of $12.57, while its current price level is -20.13% below from 52-week high level whereas it is 27.70% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $12.98 while that of 200 days or SMA-200 reads an average of $13.60. A closer look into the stock’s movement over the week reveals that its volatility is standing at 2.57% during that period while stretching the period over a month that increases to 2.99%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.70 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Goldman which initiated the stock as “Neutral” in its note to investors issued on February 01, 2024, recommending a price target of $20 for it. Goldman issued its recommendations for the stock as it resumed the price target for the stock is $38.
Over the week, DVAX’s stock price is moving -0.58% down while it is -1.47% when we observe its performance for the past one month. Year-to-date it is -13.45% down and over the past year, the stock is showing an upside performance of 22.59%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of $0 beat the consensus estimate of -$0.01 for the same. For DVAX, analysts are forecasting an EPS-growth rate of 620.00% for current year and estimate for EPS growth in next year is 96.20%. In next quarter, company is expected to be making quarterly sales of $78.37 million as analysts are expecting the sales for current fiscal year at $287.96 million and seeing the company making $347.37 million in sales next year. Moreover, analysts are in estimates of $55.67 million for current-quarter revenue.
Currently, Dynavax Technologies Corp.’s total number of outstanding shares is 130.62M with 0.29% of that held by the insiders while 98.12% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -0.73% and return on equity (ROE) at -1.06%. It has a 27.18 of forward P/E ratio. Stock’s beta reads 1.26. Stock has a price to book (P/B) ratio of 2.52 while price to sale or P/S ratio amounts to 6.80. Its return on asset (ROA) is -0.64% on average.
